Printer Friendly

SECRETARY OF AGRICULTURE APPOINTS MYCOGEN CORP. CHAIRMAN TO ALTERNATIVE AGRICULTURE RESEARCH AND COMMERCIALIZATION BOARD

 SECRETARY OF AGRICULTURE APPOINTS MYCOGEN CORP. CHAIRMAN
 TO ALTERNATIVE AGRICULTURE RESEARCH AND COMMERCIALIZATION BOARD
 SAN DIEGO, March 18 /PRNewswire/ -- Mycogen Corp. (NASDAQ: MYCO) announced today that Jerry Caulder, chairman, president and chief executive officer of Mycogen Corp., has been appointed by Secretary of Agriculture Edward Madigan to serve on the newly formed Alternative Agriculture Research and Commercialization (AARC) Board.
 The board was designated by Congress under the 1990 Farm Bill to establish policy, implement programs and direct the activities of an independent center within the U.S. Department of Agriculture (USDA) whose charter will be to expand industrial uses of farm and forest products. The nine-member board will report directly to the secretary.
 Madigan called the new center and its board a key component of the new uses initiative he announced at the USDA's December Outlook Conference.
 "Installing this board and establishing the AARC Center will boost our efforts to move research out of the laboratory and into the marketplace," Madigan said.
 One of the board's first tasks will be the selection of an executive director for the center. Staff for the center will be assembled from current USDA employees.
 In addition to his position as chief executive officer of Mycogen, Caulder served from 1989 to 1991 as chairman of the board of the Industrial Biotechnology Association, a Washington D.C.-based trade association that focuses on regulatory issues involved in preparing the marketplace for biotechnology products.
 Mycogen Corp. provides crop protection products and services. The company develops, manufactures and markets environmentally compatible products based on naturally occurring agents to control insects, parasites, weeds and other pests. Mycogen develops its products through the application of genetic engineering techniques and innovative formulations.
 -0- 3/18/92 R
 /CONTACT: Marie C. Burke of Mycogen Corp., 619-453-8030/
 (MYCO) CO: Mycogen Corporation ST: California IN: CHM SU:


KJ-JL -- SD002 -- 9254 03/18/92 12:51 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 18, 1992
Words:312
Previous Article:LA ROCHE COLLEGE BRINGS HARVARD LEGAL ETHICIST TO PITTSBURGH
Next Article:ANTARCTICA GETS MULTIMILLION DOLLAR CLEAN-UP
Topics:


Related Articles
MYCOGEN SIGNS INTERNATIONAL LICENSE AGREEMENT WITH KUBOTA
MYCOGEN SIGNS INTERNATIONAL LICENSE AGREEMENT WITH KUBOTA
MYCOGEN RECEIVES APPROVAL IN SPAIN FOR MVP(R) BIOINSECTICIDE; FIRST APPROVAL IN EUROPE FOR A MYCOGEN CELLCAP(R) ENCAPSULATED PRODUCT
MYCOGEN HIRES PRESIDENT TO HEAD NEW SUBSIDIARY FOCUSING ON ANIMAL AND HUMAN HEALTH MARKETS
MYCOGEN ANNOUNCES SECOND QUARTER RESULTS
MYCOGEN'S MVP(R) BECOMES FIRST GENETICALLY ENGINEERED BIOPESTICIDE REGISTERED FOR COMMERCIAL SALE IN FRANCE
MYCOGEN ANNOUNCES CFO'S DEPARTURE
MYCOGEN, DOWELANCO FINALIZE STRATEGIC ALLIANCE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters